Strategic Wealth Partners, Ltd. Vertex Pharmaceuticals Inc Transaction History

Strategic Wealth Partners, Ltd.

$892 Million
Q1 2024

A detailed history of Strategic Wealth Partners, Ltd. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Strategic Wealth Partners, Ltd. holds 2,853 shares of VRTX stock, worth $1.34 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares

2,853

Previous 2,393 19.22%

Holding current value

$1.34 Million

Previous $973,000 22.51%

% of portfolio

0.13%

Previous 0.12%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 20, 2024	BUY	$407.69 - $446.08 $187,537 - $205,196	460 Added 19.22%	2,853 $1.19 Million
Q4 2023 May 20, 2024	BUY	$343.0 - $410.68 $100,842 - $120,739	294 Added 14.01%	2,393 $973,000
Q3 2023 May 20, 2024	SELL	$338.18 - $362.46 $15,218 - $16,310	-45 Reduced 2.1%	2,099 $729,000
Q2 2023 May 20, 2024	BUY	$314.42 - $351.91 $3,773 - $4,222	12 Added 0.56%	2,144 $754,000
Q1 2023 Apr 24, 2023	BUY	$283.23 - $323.1 $49,282 - $56,219	174 Added 8.89%	2,132 $671,000

Q4 2022 Apr 24, 2023	BUY	$285.76 - $321.48 $559,518 - $629,457	1,958 New	1,958 $565,000
Q2 2021 Aug 25, 2021	SELL	$187.49 - $221.1 $471,349 - $555,845	-2,514 Closed	0 $0
Q1 2021 May 24, 2021	BUY	$207.02 - $241.31 $307,838 - $358,827	1,487 Added 144.79%	2,514 $540,000
Q4 2020 Feb 18, 2021	BUY	$207.01 - $276.09 $212,599 - $283,544	1,027 New	1,027 $243,000
Q2 2018 Sep 04, 2018	SELL	$145.72 - $169.96 $16,466 - $19,205	-113 Closed	0 $0
Q1 2018 Jul 13, 2018	BUY	$151.6 - $177.13 $17,130 - $20,015	113 New	113 $18,000

Others Institutions Holding VRTX

# of Institutions

1,623

Shares Held

222M

Call Options Held

1.35M

Put Options Held

1.49M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $120B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Strategic Wealth Partners, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Strategic Wealth Partners, Ltd. with notifications on news.

Account

Strategic Wealth Partners, Ltd. Vertex Pharmaceuticals Inc Transaction History